Amantadine-induced multiple spike waves on an electroencephalogram of a schizophrenic patient

World Journal of Biological Psychiatry

Volumn 1, Issue 1, 2000, Pages 59-64

  Ohta, Katsuya ^a   Matsushima, Eisuke ^a   Matsuura, Masato ^b   Toru, Michio ^a   Kojima, Takuya ^b  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b Ninon University School of Medicine   (Japan)

Author keywords

amantadine hydrochloride; dopamine; EEG; generalised convulsion; Pisa syndrome

Indexed keywords

AMANTADINE; DOPAMINE RECEPTOR STIMULATING AGENT;

ARTICLE; BRAIN; CASE REPORT; CHEMICALLY INDUCED DISORDER; ELECTROENCEPHALOGRAPHY; FEMALE; GENERALIZED EPILEPSY; HUMAN; MIDDLE AGED; PATHOPHYSIOLOGY; SCHIZOPHRENIA;

AMANTADINE; BRAIN; DOPAMINE AGENTS; ELECTROENCEPHALOGRAPHY; EPILEPSY, GENERALIZED; FEMALE; HUMANS; MIDDLE AGED; SCHIZOPHRENIA;

EID: 0033993362     PISSN: 15622975     EISSN: 18141412     Source Type: Journal    
DOI: 10.3109/15622970009150567     Document Type: Article

References (40)

1. Alam SM, Starr MS (1993) Dopaminergic modulation of pilocarpine-induced motor seizures in the rat: the role of hippocampal D2 receptors. Neuroscience 53:425-431.
2. Amabeoku G, Chikuni O (1994) GABAergic and dopaminergic systems may be involved in seizures induced by pyrimethamine in mice. Gen Pharmacol 25:1269-1277.
3. American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental Disorders, 4th edn [DSM-IV], American Psychiatric Association, Washington DC.
4. Bailey EV, Stone TW (1975) The mechanism of action of amantadine in Parkinsonism: a review. Arch Int Pharmacodyn Ther 216:246-262.
5. Barone P, Palma V, Bartolomeis A, Cicarelli G, Campanella G (1992) Dopaminergic regulation of epileptic activity. Neurochemistry International 20: Suppl 245S-249S.
6. Berretta N, Berton H, Bianchi R, Capogna W, Francesconi W, Brunelli M (1990) Effects of dopamine, D-1 and D-2 dopaminergic agonists on the excitability of hippocampal CA1 pyramidal cells in guinea pig. Exp Brain Res 83:124-130.
7. Bonuccelli U, Garant DS, Maggio R, Fariello R (1994) Motor expression of kainic acid seizures is attenuated by dopamine depletion in mice. Brain Res 657:269-274.
8. Bower DJ, Chalasani P, Ammons JC (1994) Withdrawal-induced neuroleptic malignant syndrome. Am J Psychiatry 151:451-452.
9. Brown CR, Hernandez K, Kelly MT (1987) Hyperthermia and death from amantadine overdose. Vet Hum Toxicol 29:463.
10. Cedarbaum JM, Schleifer LS (1990) Drugs for Parkinson's disease, spasticity, and acute muscle spasms. In: Cilman AC, Rail TW, Nies AS (eds) The pharmacological basis of therapeutics. Pergamon Press, New York, 8th ed, pp 472-473.
11. Davies WL, Crunert RR, Haff RF, McGahen JW, Neumayer EM, Paulshock M, Watts JC, Wood TR, Hermann EC, Hoffmann CE (1964) (1964) Antiviral activity of 1-adamantanamine (amantadine). Science 144:862-863.
12. Dinan TC, Crunelli V, Kelly JS (1987) Neuroleptics decrease calcium-activated potassium conductance in hippocampal pyramidal cells. Brain Res 407:159-162.
13. Douglas RC (1990) Antimicrobial agents. In: Cilman AC, Rail TW, Nies AS (eds) The pharmacological basis of therapeutics. Pergamon Press, New York, 8th ed, pp 1191-1192.
14. Ekbom K, Lindholm H, Ljungberg L (1972) New dystonic syndrome associated with butyrophenone therapy. Zeitschrift fur Neurologie 202:94-103.
15. Farnebo LO, Fuxe K, Goldstein M, Hamberger B (1971) Dopamine and noradrenaline releasing action of amantadine in the central and peripheral nervous system: a possible mode of action in Parkinson's disease. Eur J Pharmacol 16:27-38.
16. Fletcher EA, Redfern PH (1970) The effect of amantadine on the uptake of dopamine and noradrenaline by rat brain homogenates. J Pharm Pharmacol 22:957-959.
17. Gualtieri T, Chandler M, Coons TB, Brown LT (1989) Amantadine: a new clinical profile for traumatic brain injury. Clin Neuropharmacol 12:258-270.
18. Heimans RLH, Rand MJ, Fennessy MR (1972) Effects of amantadine on uptake and release of dopamine by a particular fraction of rat basal ganglia. J Pharm Pharmacol 24:875-879.
19. Hirasawa H, Ohkubo Y, Atsumi Y, Kojima T, Shimazono Y (1984) Effects of amantadine hydrochloride on the clinical symptons and EEG of dementia. Japanese Journal of Clinical Psychiatry 13:81-88.
20. Horiguchi J, Inami Y, Shoda T (1990) Effects of long-term amantadine treatment on clinical symptoms and EEG of a patient in a vegetative state. Clin Neuropharmacol 13:84-88.
21. Imamura T, Suzuki K, Yamadori A, Sahara M, Nagasawa H, Itoh M, Itoh H (1994) Improved perseveration with amantadine. Brain St Nerve 46:556-562.
22. Kaneko S, Okada M, Hirano T, Kondo T, Otani K, Fukushima Y (1993) Carbamazepine and zonisamide increase extracellular dopamine and serotonin levels in vivo, and carbamazepine does not antagonize adenosine effect in vitro: mechanisms of blockade of seizure spread. Japanese Journal of Psychiatry and Neurology 47:371-373.
23. Kleinrok Z, Czuczwar SJ, Kozicka M (1980) Effect of dopaminergic and CABA-ergic drugs given alone or in combination on the anticonvulsant action of phenobarbital and diphenylhydantoin in the electroshock test in mice. Epilepsia 21:519-529.
24. Muller HF, Dastoor DP, Klingner A, Cole M, Boillat J (1979) Amantadine in senile dementia: electroencephalographic and clinical effects. J Am Ceriatr Soc 27, 9-16.
25. Pieretti S, Giannuario AD, Sagratella S (1995) 3-(3-hydroxyphenyl)-N-(1- propyl) piperidine elicits convulsant effects in mice. Gen Pharmacol 26:623-626.
26. Quesney LF, Andermann DF, Gloor P (1981) Dopaminergic mechanism in generalized photosensitive epilepsy. Neurology 31:1542-1544.
27. Richfield EK, Penney JB, Young AB (1989) Anatomical and affinity state comparisons between dopamine D1 and D2 receptors in the rat central nervous system. Neuroscience 30:767-777.
28. Scatton B, Cheramy A, Besson MJ, Glowinsky J (1970) Increased synthesis and release of dopamine in the striatum of the rat after amantadine treatment. Eur J Pharmacol 13:131-133.
29. Schwab RS, England AC, Poskanzer DC, Young RR (1969) Amantadine in the treatment of Parkinson's disease. JAMA 208:1168-1170.
30. Shahar EM, Brand N (1992) Effect of add-on amantadine therapy for refractory absence epilepsy. J Pediatr 121:819-821.
31. Shalev RS, Steinberg A, Lubetzki-Korn I, Amir N (1987) Amantadine: effective adjuvant therapy for intractable seizures. Neurology 37:350.
32. Shields WD, Lake JL, Chugani HT (1985) Amantadine in the treatment of refractory epilepsy in childhood: an open trial in 10 patients. Neurology 35:579-81.
33. Smialowski A, Bijak M (1987) Excitatory and inhibitory action of dopamine on hippocampal neurons in vitro. Involvement of D2 and D1 receptors. Neuroscience 23:95-101.
34. Smialowski A (1990) Inhibition of low calcium induced epileptiform discharges in the hippocampus by dopamine D1 receptor agonist, SKF 38393. Brain Res 528:148-150.
35. Snoey ER, Bessen HA (1990) Acute psychosis after amantadine overdose. Ann Emerg Med 19:668-670.
36. Starr MS (1996) The role of dopamine in epilepsy. Synapse 22:159-94
37. Suitsu N (1992) A computer-assisted EEG study on psychotropic properties of antiparkinsonian drugs. Seishin Shinkeigaku Zasshi 94:238-262.
38. Terzano MC, Montanari E., Calzetti S, Mancia D, Lechi A (1983) The effect of amantadine on arousal and EEG patterns in Creutzfledt-Jakob disease. Arch Neurol 40:555-559.
39. Toru M, Matsuda O, Makiguchi K, Sugano K (1981) Neuroleptic malignant syndrome-like state following a withdrawal of antiparkinsonian drugs. J Nerv Ment Dis 169:324-327.
40. Von Voigtlander PF, Moore KE (1971) Dopamine: release from the brain in vivo by amantadine. Science 174:408-409.